Advertisement
Singapore markets open in 3 hours 42 minutes

  • Straits Times Index

    3,144.76
    -38.85 (-1.22%)
     

  • S&P 500

    5,051.41
    -10.41 (-0.21%)
     

  • Dow

    37,798.97
    +63.86 (+0.17%)
     

  • Nasdaq

    15,865.25
    -19.77 (-0.12%)
     

  • Bitcoin USD

    63,254.45
    +0.70 (+0.00%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • FTSE 100

    7,820.36
    -145.17 (-1.82%)
     

  • Gold

    2,399.50
    +16.50 (+0.69%)
     

  • Crude Oil

    85.31
    -0.10 (-0.12%)
     

  • 10-Yr Bond

    4.6590
    +0.0310 (+0.67%)
     

  • Nikkei

    38,471.20
    -761.60 (-1.94%)
     

  • Hang Seng

    16,248.97
    -351.49 (-2.12%)
     

  • FTSE Bursa Malaysia

    1,535.00
    -7.53 (-0.49%)
     

  • Jakarta Composite Index

    7,164.81
    -7,286.88 (-50.42%)
     

  • PSE Index

    6,404.97
    -157.46 (-2.40%)
     

Alkermes (ALKS) Gains As Market Dips: What You Should Know

Zacks Equity Research

In the latest trading session, Alkermes (ALKS) closed at $19.52, marking a +1.61% move from the previous day. This change outpaced the S&P 500's 0.29% loss on the day. Meanwhile, the Dow lost 0.46%, and the Nasdaq, a tech-heavy index, lost 0.27%.

Coming into today, shares of the drugmaker had lost 9.6% in the past month. In that same time, the Medical sector gained 2.64%, while the S&P 500 gained 4.56%.

Wall Street will be looking for positivity from ALKS as it approaches its next earnings report date. On that day, ALKS is projected to report earnings of $0.66 per share, which would represent year-over-year growth of 94.12%. Our most recent consensus estimate is calling for quarterly revenue of $408.54 million, up 29.38% from the year-ago period.

Investors should also note any recent changes to analyst estimates for ALKS. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

ADVERTISEMENT

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ALKS is currently a Zacks Rank #3 (Hold).

Investors should also note ALKS's current valuation metrics, including its Forward P/E ratio of 33.31. This represents a premium compared to its industry's average Forward P/E of 25.1.

It is also worth noting that ALKS currently has a PEG ratio of 1.6. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.6 at yesterday's closing price.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 62, putting it in the top 25% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alkermes plc (ALKS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.